Cognex (CGNX) Receives Positive Coverage Following Q4 Beat, Conservative Guidance

Yesterday Cognex Corp (NASDAQ: CGNX) reported Q4 EPS that topped estimates on higher than expected revenue. The company also reported revenue guidance that was in-line, which analysts at Needham think was conservative.

"CGNX looks well positioned entering 2013, with several new products, although the sluggish economic environment is likely to restrain top-line growth again in the early part of the year," said analyst James Ricchiuti.

He thinks the company will grow as the global economy gains momentum.

Needham & Company reiterated a Buy rating on Cognex and raised its price target to $47.00 (from $40.00).

For an analyst ratings summary and ratings history on Cognex (NASDAQ: CGNX) click here. For more ratings news on Cognex click here.

Shares of Cognex closed at $41.52 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron Technology (MU) PT Raised to $2,100 at DA Davidson as Memory Markets Expected to Further Tighten
• Westlake Chemical (WLK) PT Lowered to $90 at Truist Securities
• Foghorn Therapeutics (FHTX) PT Lowered to $5 at Stifel